The cancer spectrum in families of carriers of pathogenic or likely pathogenic CHEK2 variants based on functional assays, was consistent with the literature including breast, early onset breast, prostate, and colorectal cancers. This evidence concerns the gene CHEK2 and colorectal cancer.